For use in healthy swine as an aid in the prevention of viremia, aid in the reduction of virus shedding and aid in the reduction of lymphoid infection cause by porcine circovirus Type 2 (PCV2), and as an aid in the reduction of lung lesions due to Mycoplasma hyopneumoniae. PCV2 efficacy for at least 20 weeks following completion of vaccination has been demonstrated.

Advantages:

- A reliable ready-to-use combination vaccine for PCV2 and Mycoplasma hyopneumoniae
  — Fight against two costly diseases with one simple, single-bottle product
  — No mixing required which reduces the risk of contamination
- Same superior efficacy, now with a 5-month PCV2 duration of immunity
- The ONLY PCV2 vaccine that’s approved for use in pigs as early as 3 days of age (two-dose option)
  — Pigs are easiest to pick up by trusted, capable handlers
  — Pigs are less likely to be stressed because they are still with their mothers
- Choose between two convenient options
  — One dose – single 2-mL intramuscular dose at 3 weeks of age or older
  — Two doses – initial 1-mL intramuscular dose as early as 3 days of age followed by a second 1-mL dose 3 weeks later
- Aids in the prevention of PCV2 viremia, which is the initial step in the development of PCV associated disease
- Merck Animal Health is the only company to bring a PCV2 vaccine to market using a PCV2 and porcine reproductive and respiratory syndrome (PRRS) co-infection challenge model
  — Predicts ability of vaccine to perform in real-world conditions
- Microsol Diluvac Forte adjuvant provides optimal immune response

Code: 121356 100mL
Option 1: 50 doses - 2mL
Option 2: 100 doses - 1mL

Code: 124428 500mL
Option 1: 250 doses - 2mL
Option 2: 500 doses - 1mL

Data on file, Merck Animal Health
Circumvent® PCV-M G2
PORCINE CIRCOVIRUS VACCINE, TYPE 2, MYCOPLASMA HYOPNEUMONIAE BACTERIN

For use in healthy swine as an aid in the prevention of viremia, aid in the reduction of virus shedding and aid in the reduction of lymphoid infection caused by porcine circovirus Type 2 (PCV2), and as an aid in the reduction of lung lesions due to Mycoplasma hyopneumoniae. PCV2 efficacy for at least 20 weeks following completion of vaccination has been demonstrated.

ADMINISTRATION AND DOSAGE OPTIONS:
Allow the vaccine to reach an ambient temperature of 16°-27°C (60°-80°F) and shake well prior to use. Use aseptic technique. OPTION 1: Vaccinate pigs intramuscularly at 3 weeks of age or older with a single 2 mL dose. OPTION 2: Vaccinate pigs intramuscularly as early as 3-5 days of age with a 1 mL dose followed by a second 1 mL dose 3 weeks later.

CAUTIONS:
Store at 2°-7°C (35°-45°F). Do not freeze. Use entire contents when first opened; do not save partial contents. Burn the container and all unused product. Use only in healthy swine. Do not vaccinate within 21 days before slaughter. The vaccine may induce significant localized adverse reactions, particularly following booster vaccination. Localized reactions resolve 1-35 days following vaccination. If allergic reaction occurs, treat with epinephrine. Caution should be used to avoid injecting your own fingers, hands, or other body parts. Accidental injection can cause serious local reactions. Contact a physician immediately.

PRESERVATIVE: Gentamicin and thimerosal.

FOR ANIMAL USE ONLY
READ AND FOLLOW LABEL DIRECTIONS
U.S. Veterinary License No. 165A
FOR VETERINARY USE ONLY

Intervet Inc. d/b/a Merck Animal Health
Omaha, Nebraska 68103 USA
1 800 521-5767